These findings need to be carefully contextualized with other studies on the relationship between SGLT2 inhibitors and hematologic cancers, where it has been hypothesized that SGLT2 is a mechanism by which adult T cell leukemia cells obtain glucose for metabolic needs, with SGLT inhibitors representing a potential novel therapeutic option.38 The gene discussed is SLC5A2; the disease is hematopoietic and lymphoid cell neoplasm.